Trials / Recruiting
RecruitingNCT07024641
A Study to Assess the Safety, Tolerability, and Pharmacokinetics of GIGA-2339 in Participants With Chronic Hepatitis B Virus Infection
A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GIGA-2339 Administered as a Single Ascending Dose and Multiple Ascending Doses in Participants With Chronic Hepatitis B Virus Infection
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 48 (estimated)
- Sponsor
- GigaGen, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary purpose of this study is to assess the safety and tolerability of single and multiple intravenous (IV) doses of GIGA-2339 in participants with chronic Hepatitis B Virus (HBV) infection.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | GIGA-2339 | Administered by intravenous infusion |
| DRUG | Placebo | Administered by intravenous infusion |
Timeline
- Start date
- 2024-11-13
- Primary completion
- 2027-09-01
- Completion
- 2027-09-01
- First posted
- 2025-06-17
- Last updated
- 2026-03-18
Locations
16 sites across 3 countries: United States, Australia, Hong Kong
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07024641. Inclusion in this directory is not an endorsement.